This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Align Tech (ALGN) and Smith & Nephew Snats (SNN)

Tipranks - Tipranks - Thu Jun 11, 6:36AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ultragenyx Pharmaceutical (RARE), Align Tech (ALGN) and Smith & Nephew Snats (SNN).

Introducing TipRanks MCP for Agents

Ultragenyx Pharmaceutical (RARE)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $79.00. The company’s shares closed last Tuesday at $22.79.

According to TipRanks.com, Ijem is a 5-star analyst with an average return of 19.1% and a 45.2% success rate. Ijem covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Rhythm Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $51.87 average price target.

See the top stocks recommended by analysts >>

Align Tech (ALGN)

Piper Sandler analyst Jason Bednar maintained a Buy rating on Align Tech today and set a price target of $235.00. The company’s shares closed last Tuesday at $178.10, close to its 52-week low of $157.57.

According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.7% and a 40.9% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Solventum Corporation, and Merit Medical Systems. ;'>

Align Tech has an analyst consensus of Moderate Buy, with a price target consensus of $208.00, a 19.2% upside from current levels. In a report issued on May 27, William Blair also maintained a Buy rating on the stock.

Smith & Nephew Snats (SNN)

In a report released today, Caitlin Roberts from Canaccord Genuity reiterated a Hold rating on Smith & Nephew Snats, with a price target of $30.00. The company’s shares closed last Tuesday at $31.32, close to its 52-week high of $31.72.

According to TipRanks.com, Roberts is a 3-star analyst with an average return of 4.4% and a 48.4% success rate. Roberts covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and REPRO-MED Systems. ;'>

Currently, the analyst consensus on Smith & Nephew Snats is a Hold with an average price target of $32.32, a 4.7% upside from current levels. In a report issued on June 4, Kepler Capital also downgraded the stock to Hold.

Read More on RARE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).